良性攝護腺肥大所導致下泌尿道症狀病人對α阻斷劑的藥物順從性-台北榮總經驗分享
劉家翔1、吳宏豪1,2,3、林登龍1,2,3、陳光國1,2,3
1臺北榮民總醫院 泌尿部2國立陽明大學 醫學院 泌尿學科 3書田泌尿科學研究中心
Drug adherence of alpha blocker for lower urinary tract symptoms related to benign prostatic hyperplasia-a single center experience
Chia-Hsiang Liu1, Howard H.H Wu1,2,3, Alex Tong-Long Lin1,2,3, Kuang-Kuo Chen1,2,3
1Department of Urology, Taipei Veterans General Hospital, Taipei , Taiwan; 2Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 3Shu-Tien Urological Science Research Center , Taipei, Taiwan
Purpose:
Alpha blocker is the initial treatment for benign prostatic hyperplasia(BPH).The objective of this study is to perform a review of adherence of alpha blocker in taipei veterans general hospital.
Materials and Methods:
The sample population consisted of men aged 40 year old or older who were newly diagnosed with BPH during the index period from January 1, 2012 to December 31, 2014. Only Alpha blockers was considered in the analysis. Patients were followed until BPH surgery or the last follow-up.
Results:
Among 6670 patients, the 1-yr adherence was 10% in patients exposed to at least 3-mo therapy. Overall hospitalization rates BPH surgery were 3.33 per 100 patient-years. Limitations include the paucity of clinical measures and the absence of patient-reported outcomes
Conclusion:
Adherence to Alpha blocker for BPH is low and could affect clinical outcomes.